Halecord 100/6, Halecord 200/6 & Halecord 400/12 100/6 mcg, 200/6 mcg, 400/12 mcg Inhalation Powder
PDF Leaflet Revision Date: 02 June 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of asthma and COPD.
Dosage (summary)
Adults: 1 inhalation as needed; maintenance: 2 inhalations daily.
Onset of Action / Duration
Onset: 1-3 mins, Duration: at least 12 hours
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Use in pregnancy only if benefits outweigh risks; budesonide excreted in breast milk.
Key Drug Interactions
- CYP3A4 inhibitors
- Beta-adrenergic blockers
- QT prolonging agents
Contraindications
- Hypersensitivity to components
- Children under 12 years
Common side effects
- Palpitations
- Headache
- Cough
- Hoarseness
Counselling Points
- Rinse mouth after use
- Use even when asymptomatic
- Monitor for worsening symptoms
Serious warnings
- Not for acute exacerbations
- Risk of pneumonia in COPD
Important Disclaimer
The Halecord 100/6, Halecord 200/6 & Halecord 400/12 100/6 mcg, 200/6 mcg, 400/12 mcg Inhalation Powder professional information leaflet below is the property of Innovata Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
